This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Spero Therapeutics’s 8K filing here.
About Spero Therapeutics
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.
Further Reading
- Five stocks we like better than Spero Therapeutics
- The Basics of Support and Resistance
- ServiceNow Targets New Highs With AI and Automation
- What Do S&P 500 Stocks Tell Investors About the Market?
- Zymeworks in Focus for Insider Activity: Catalysts Ahead
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Kura Sushi Stock Dips Into a Hot Buying Opportunity
